Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Change in Receivables (2019 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Change in Receivables for 7 consecutive years, with $6.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables rose 134.17% year-over-year to $6.4 million, compared with a TTM value of $12.0 million through Dec 2025, up 274.39%, and an annual FY2025 reading of $12.0 million, up 274.39% over the prior year.
  • Change in Receivables was $6.4 million for Q4 2025 at Zevra Therapeutics, up from -$1.4 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $8.7 million in Q1 2021 and bottomed at -$9.4 million in Q2 2021.
  • Average Change in Receivables over 5 years is $995400.0, with a median of $1.2 million recorded in 2022.
  • The sharpest move saw Change in Receivables tumbled 5376.74% in 2021, then soared 2436.26% in 2022.
  • Year by year, Change in Receivables stood at -$91000.0 in 2021, then skyrocketed by 2436.26% to $2.1 million in 2022, then surged by 250.42% to $7.4 million in 2023, then plummeted by 63.5% to $2.7 million in 2024, then skyrocketed by 134.17% to $6.4 million in 2025.
  • Business Quant data shows Change in Receivables for ZVRA at $6.4 million in Q4 2025, -$1.4 million in Q3 2025, and $4.9 million in Q2 2025.